

This is the English translation of a Japanese press release published on November 6, 2025. If there are any differences in content or interpretation, the Japanese version shall prevail.

November 6, 2025

Notification Regarding Status of Acquisition of Treasury Shares

(Acquisition of the company's own shares under the regulations of the Articles of Incorporation pursuant to Article 165, paragraph (2) of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) is pleased to announce the current status of the acquisition of its own shares pursuant to Article 156 of the Companies Act of Japan (the Companies Act), as applied under Article 165, paragraph (3) of the Companies Act, as previously announced on July 10, 2025. The details are as follows:

- | | |
|-------------------------------------|---|
| 1. Type of shares acquired | Common share of Hisamitsu Pharmaceutical |
| 2. Total number of shares acquired | 431,200 shares |
| 3. Total amount of acquisition cost | 1,761,453,600 yen |
| 4. Period for acquisition | From October 1, 2025 to October 31, 2025
(based on contract) |
| 5. Method of acquisition | Purchase in the open market through
discretionary trading on the Tokyo Stock
Exchange |

(Reference)

1. Details of Resolution of the board of directors meeting held on July 10, 2025

- | | |
|---|---|
| (1) Type of shares to be acquired | Common share of Hisamitsu Pharmaceutical |
| (2) Total number of shares to be acquired | 3 million shares (Maximum)
4.09% of total number of outstanding shares
[excluding treasury shares] |
| (3) Total amount of acquisition cost | 15 billion yen (Maximum) |
| (4) Period for acquisition | From July 11, 2025, to December 31, 2025 |
| (5) Method of acquisition | (i) Acquire through an off-auction own share
repurchase transaction (ToSTNeT-3)
(ii) Acquire in the open market through
discretionary trading on the Tokyo Stock
Exchange |

2. Cumulative total of treasury shares acquired based on the above resolutions of the board of directors meeting (as of October 31, 2025)

- | | |
|--------------------------------------|--------------------|
| (1) Total number of shares acquired | 2,745,400 shares |
| (2) Total amount of acquisition cost | 11,217,473,700 yen |